An FDA advisory committee has voted in favor of Sage's Zulresso (brexanolone) for the treatment of postnatal depression, marking a significant step towards its approval as the first specific drug for this condition. However, the same panel rejected Alkermes' ALKS 5461 for major depressive disorder, citing concerns over its benefit-risk profile and trial design.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.